¸²ÇÁÁ¾ ȯÀÚ¿¡¼ ¸®Åö½Ã¸¿ Ä¡·á ÈÄ¿¡ ¹ß»ýÇÑ Àú°¨¸¶±Û·ÎºÒ¸°Ç÷Áõ 1¿¹
A Case of Prolonged Hypogammaglobulinemia after Rituximab-Containing Chemotherapy in a Patient with Lymphoma
´ëÇѳ»°úÇÐȸÁö 2014³â 87±Ç 3È£ p.357 ~ p.362
³ëÇöÁø(Noh Hyun-Jin) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
°øºÀÇÑ(Gong Bong-Han) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è¿µ½Å(Kim Young-Sin) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¤À±È(Jung Yun-Hwa) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¿ìÀμ÷(Woo In-Sook) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÇÑÄ¡È(Han Chi-Hwa) - °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
ÀúÀÚµéÀº B¼¼Æ÷¸²ÇÁÁ¾ ȯÀÚ¿¡¼ rituximabÀÌ Æ÷ÇÔµÈ Ç×¾ÏÄ¡·á ÈÄ 2³â ÀÌ»ó Áö¼ÓµÈ Àú°¨¸¶±Û·ÎºÒ¸°Ç÷ÁõÀ» °æÇèÇÏ¿´±â¿¡ ¹®Çå°íÂû°ú ÇÔ²² º¸°íÇÑ´Ù.
Rituximab, an anti-CD20 monoclonal antibody, is an effective target agent against the B lymphocytes in B-cell lymphoid malignancies and various lymphoproliferative diseases. Moreover, the toxicity of rituximab is less severe than that of conventional cytotoxic agents, which has promoted the widespread application of rituximab in the treatment of B-cell lymphoma. However, depletion of B lymphocytes by rituximab, which leads to secondary hypogammaglobulinemia, can cause deterioration of humoral immunity. Although immune reconstitution after hematopoietic stem cell transplantation is known to prevent prolonged hypogammaglobulinemia, very few cases of long-standing hypogammaglobulinemia have been reported. We report herein a case of prolonged hypogammaglobulinemia after rituximab-containing chemotherapy and splenectomy in a patient with non-Hodgkin¡¯s lymphoma and discuss the clinical significance and pathogenetic mechanism of this phenomenon with a literature review.
Å°¿öµå
ºñÈ£ÁöŲ¸²ÇÁÁ¾, ¸®Åö½Ã¸¿, ¸é¿ª±Û·ÎºÒ¸° G °áÇÌ
Non-Hodgkin¡¯s lymphoma, Rituximab, IgG deficiency
KMID :
0882420140870030357
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)